

Pharmacist Guidance for Dispensing CLARUS® (Isotretinoin Capsules, USP)

CLARUS® (Isotretinoin Capsules, USP) belongs to the retinoid class of drugs that cause severe birth defects. Fetal exposure to CLARUS®, even for short periods of time, presents a high risk of congenital malformations and miscarriage.

CLARUS® is therefore strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions in the CLARUS® Pregnancy Prevention Program are met.

1. It is strongly recommended that each CLARUS® prescription be limited to a one-month supply in order to encourage patients to return for follow-up to monitor side-effects.

Prescriptions of CLARUS® for **women of childbearing potential** should be limited to **30 days** of treatment. Continuation of treatment requires a new prescription. Dispensing should occur within **7 days** from the date of the prescription.

- i. Under the Pregnancy Prevention Program prescriptions presented more than **7 days** after the prescription date should be considered expired and the patient should be instructed to get a new prescription from their prescriber. For some female patients this may require a further negative pregnancy test.
- ii. Two reliable forms of contraception must be used simultaneously, even by female patients who normally do not employ contraception due to infertility or who claim absence of sexual activity or who have amenorrhea.

2. **All patients** should be instructed:

- Never to give this medicine to another person, especially a female patient.
- To return any unused capsules to their pharmacist at the end of treatment.
- Not to donate blood during therapy and for 1 month following discontinuation of CLARUS® because of the potential risk to the fetus of a pregnant transfusion recipient.

3. For more information and additional Health Care Professional materials please visit www.claruscLEARprogram.ca

To report an Adverse Event, please contact the Viatris Medical Information Department (toll-free) at 1-844-596-9526.

Please consult the product monograph at www.claruscLEARprogram.ca/en-ca/for-healthcare-professionals/clear-overview for important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The product monograph is also available by calling us at 1-844-596-9526.

This material is part of the Risk Minimization plan for CLARUS®. This material is not intended for promotional use.



CLARUS® is a registered trademark of Mylan Pharmaceuticals ULC, a Viatris company.
VIATRIS and VIATRIS & Design are registered trademarks of Mylan Inc., used under permission by Mylan Pharmaceuticals ULC, a Viatris company.
©2025 Viatris Inc. All rights reserved.